Advanced Proteome Therapeutics to Proceed with Its Proposed Plan of Arrangement
Burnaby, British Columbia--(Newsfile Corp. - March 6, 2023) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E81) ("APC" or the "Company") is pleased to announce that all conditions have been satisfied or waived and the Board of Directors of the Company has authorized the Company to complete its plan of arrangement under the Business Corporations Act (British Columbia) (the "Arrangement") as set forth in the Company's Management Information Circular dated January 17, 2023 and...
2023-03-06 6:47 PM EST
Advanced Proteome Therapeutics Announces Its Proposed Plan of Arrangement
Burnaby, British Columbia--(Newsfile Corp. - January 17, 2023) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E81) ("APC" or the "Company") is pleased to announce that the Supreme Court of British Columbia (the "Court") has issued an interim order (the "Interim Order") on January 16, 2023 in connection with the Company's proposed Plan of Arrangement (see below). The Interim Order, among other things, authorizes the holding of an annual and special meeting (the "Meeting") of...
2023-01-17 2:39 PM EST
Advanced Proteome Therapeutics Announces Closing of Non-Brokered Private Placement
Burnaby, British Columbia--(Newsfile Corp. - December 23, 2022) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E81) ("APC" or the "Company") is pleased to announce that, subject to the approval of the TSX Venture Exchange, it has closed a non-brokered private placement (the "Private Placement" or the "Offering") raising gross proceeds of $72,500.00 by the issuance of 1,450,000 shares at a price of $0.05 per share.There were no finders' fees paid in connection with the Private...
2022-12-23 5:08 PM EST
Advanced Proteome Therapeutics Announces Appointment of Mr. Cory Brandolini to the Board of Directors
Vancouver, British Columbia--(Newsfile Corp. - November 21, 2022) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E8) ("APC" or the "Company") is pleased to announce that it has appointed Mr. Cory Brandolini to the board of directors.Mr. Brandolini has over 3 decades of experience in the capital markets and as an advisor to disruptive, high growth software companies across many verticals in the technology sector. Over the course of his career, he has helped raise hundreds of...
2022-11-21 7:40 PM EST
Advanced Proteome Therapeutics Manuscript Published in Bioconjugate Chemistry
Vancouver, British Columbia--(Newsfile Corp. - August 17, 2022) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E81) ("APC" or the "Company"), is pleased to announce that its US subsidiary, Advanced Proteome Therapeutics Inc. ("APTI"), has had its technology featured in a peer-reviewed publication.The manuscript entitled, "Lysine-Directed Site-Selective Bioconjugation for the Creation of Radioimmunoconjugates" by Sarrett, et al. has been published in the prestigious journal,...
2022-08-17 8:30 AM EDT
Advanced Proteome Therapeutics Receives Issued Patent
Vancouver, British Columbia--(Newsfile Corp. - August 3, 2022) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E81) ("APC" or the "Company") is pleased to announce that the United States Patent and Trademark Office has issued a patent to its US subsidiary, Advanced Proteome Therapeutics Inc. ("APTI").On August 2, 2022, APTI was issued U.S. Patent No. 11,400,165 titled 'Composition and method for modifying polypeptides'. The patent covers highly site-selective antibody...
2022-08-03 1:45 PM EDT
Advanced Proteome Therapeutics Receives Notice of Allowance for Patent Claims
Vancouver, British Columbia--(Newsfile Corp. - April 13, 2022) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E8) ("APC" or the "Company") is pleased to announce that its US subsidiary, Advanced Proteome Therapeutics Inc. ("APTI") has received a notice of allowance for patent claims covering key intellectual property.APTI has been informed that the first set of claims from US patent application 16/180,960 have been allowed. These claims cover highly site-selective antibody...
2022-04-13 10:28 AM EDT
Advanced Proteome Therapeutics Announces Warrant Extension
Vancouver, British Columbia--(Newsfile Corp. - March 18, 2022) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E81) ("APC" or the "Company") announces that, it has applied to the TSX Venture Exchange for approval to amend the expiration of certain outstanding warrants (the "Warrants"). The Warrants' exercise price and original expiry date are detailed below. The Warrants expiry date is to be extended to September 30, 2022. The warrants to be amended do not include any warrants...
2022-03-18 3:46 PM EDT
Advanced Proteome Therapeutics Update on Plans for 2022
Vancouver, British Columbia--(Newsfile Corp. - February 3, 2022) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E81) ("APC" or the "Company"), is pleased to announce that its US subsidiary, Advanced Proteome Therapeutics Inc. ("APTI") is providing an update on plans for the upcoming year.APTI is pleased to report that, after operational advancements and continued antibody-drug conjugate (ADC) platform development and validation in 2021, 2022 is expected to be a...
2022-02-03 2:50 PM EST
Advanced Proteome Therapeutics Expands Operations
Vancouver, British Columbia--(Newsfile Corp. - November 23, 2021) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E81) ("APC" or the "Company"), is pleased to announce that its US subsidiary, Advanced Proteome Therapeutics Inc. ("APTI") is expanding operations with a new hire and additional lab space.APTI is pleased to report that it has hired an organic chemist and acquired lab space for mammalian cell culture in the Boston University BioSquare facility. The expansion is part...
2021-11-23 10:48 AM EST
Advanced Proteome Therapeutics Technology Featured in Oral Presentation at the World Molecular Imaging Congress
Vancouver, British Columbia--(Newsfile Corp. - October 4, 2021) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E8) ("APC" or the "Company"), is pleased to announce that its US subsidiary, Advanced Proteome Therapeutics Inc. ("APTI") will have its technology featured in an oral presentation at the World Molecular Imaging Congress.As previously announced, APTI and the Zeglis lab at the City University of New York, are pursuing a collaboration to investigate APTI's...
2021-10-04 11:14 AM EDT
Advanced Proteome Therapeutics Provides Update on COVID Program
Burnaby, British Columbia--(Newsfile Corp. - August 24, 2021) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E8) ("APC" or the "Company"), reports that its US subsidiary, Advanced Proteome Therapeutics Inc. ("APTI"), is dedicating additional resources to its SARS-CoV-2 protease inhibitor program.As previously announced, APTI's scientists identified multiple compounds with high predicted affinity for the main SARS-CoV-2 protease by in silico modeling and synthetic efforts and...
2021-08-24 9:45 AM EDT
Advanced Proteome Therapeutics Announces Appointment of Dr. Benjamin Krantz to CEO
Burnaby, British Columbia--(Newsfile Corp. - July 21, 2021) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E8) ("APC" or the "Company") is pleased to announce that as previously planned, Dr. Benjamin Krantz has taken over the role of CEO at its US subsidiary, Advanced Proteome Therapeutics Inc. ("APTI").Prior to this appointment, Benjamin Krantz MD, MBA was the Chief Fellow in hematology/oncology at New York University Langone Medical Center and served on the Board of...
2021-07-21 8:30 AM EDT
Advanced Proteome Therapeutics Announces Renowned Scientist to Join Scientific Advisory Board and New Chemistry Hire
Vancouver, British Columbia--(Newsfile Corp. - June 9, 2021) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E8) ("APC" or the "Company") reports that its US subsidiary, Advanced Proteome Therapeutics Inc. ("APTI") has a appointed a new Scientific Advisory Board Member and hired a new lead chemist.APTI is pleased to report that Dr. Ravi Chari is joining the Company's Scientific Advisory Board and Dr. Rajeshkumar Manian is joining as the lead organic chemist. Dr. Chari has over...
2021-06-09 1:40 PM EDT
Advanced Proteome Therapeutics Announces Closing Final Tranche of Non-Brokered Private Placement
Burnaby, British Columbia--(Newsfile Corp. - April 13, 2021) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E81) ("APC" or the "Company") is pleased to announce that, further to its news release of March 11, 2021 and subject to the approval of the TSX Venture Exchange, it has closed the final tranche of its non-brokered private placement (the "Private Placement") raising gross proceeds of $524,610 by the issuance of 2,559,073 units at a price of $0.205 per unit.Each unit...
2021-04-13 5:12 PM EDT
Advanced Proteome Therapeutics Announces Increase of Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - March 11, 2021) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E8) ("APC" or the "Company") is pleased to announce that it has increased its previously announced private placement financing (see March 1st, 2021 news release) from up to 6,097,561 units of the Company ("units) to up to 7,317,073 Units at a price of $0.205 per unit for gross proceeds of up to $1,500,000. Each unit will consist of one common share and one...
2021-03-11 1:38 PM EST
Advanced Proteome Therapeutics Announces a Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - March 1, 2021) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E8) ("APC" or the "Company") announces that, subject to the approval of the TSX Venture Exchange (the "Exchange"), it proposes to raise up to $1,250,000 through a non-brokered private placement of up to 6,097,561 units at a price of $0.205 per unit. Each unit will consist of one common share and one transferable common share purchase warrant of the Company, with each...
2021-03-01 1:11 PM EST
Advanced Proteome Therapeutics Announces Dr. Benjamin Krantz to Join Company as CEO
Burnaby, British Columbia--(Newsfile Corp. - December 17, 2020) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E8) ("APC" or the "Company'), is pleased to announce that Dr. Benjamin Krantz will be joining the Company's US subsidiary Advanced Proteome Therapeutics Inc. ("APTI") as CEO following the completion of his oncology fellowship at NYU Langone Health on July 1st, 2021. Bill Dickie will continue his role as interim CEO of APTI until then and remain a member of the board...
2020-12-17 1:02 PM EST
Advanced Proteome Therapeutics Provides Project Update
Vancouver, British Columbia--(Newsfile Corp. - August 14, 2020) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E8) ("APC" or the "Company"), is pleased to announce that its US subsidiary, Advanced Proteome Therapeutics Inc. ("APTI"), is rapidly advancing three projects with the potential to add significant shareholder value.As previously announced, APTI's scientists have identified multiple compounds with high predicted affinity for the SARS-CoV-2 main protease that exceed...
2020-08-14 10:45 AM EDT
Advanced Proteome Therapeutics Files Provisional IP for Compounds Targeting SARS-CoV-2
Burnaby, British Columbia--(Newsfile Corp. - July 9, 2020) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E8) ("APC" or the "Company"), is pleased to announce that its US subsidiary, Advanced Proteome Therapeutics Inc. ("APTI"), has filed for patent protection on a family of therapeutic candidates against SARS-CoV-2, the virus which causes COVID-19 and has initiated a project to rapidly manufacture test quantities of these drugs. As previously announced, APTI's scientists...
2020-07-09 3:23 PM EDT